Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Yu ZengDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, 8847 Riverside Pkwy, Bryan, TX 77807, USA.
Mengqiu JiangCenter for Phage Technology, Department of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Blvd., College Station, TX 77843, USA.
Sally RobinsonDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Rd, North Grafton, MA 01536, USA.ORCID 0000-0003-4711-1667
Zeyu PengDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, 8847 Riverside Pkwy, Bryan, TX 77807, USA.
Vikas ChoniraDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, 8847 Riverside Pkwy, Bryan, TX 77807, USA.ORCID 0000-0002-9688-313X
Rudo SimeonDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, 8847 Riverside Pkwy, Bryan, TX 77807, USA.
Saul TziporiDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Rd, North Grafton, MA 01536, USA.
Junjie ZhangCenter for Phage Technology, Department of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Blvd., College Station, TX 77843, USA.ORCID 0000-0002-7912-0819
Zhilei ChenDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, 8847 Riverside Pkwy, Bryan, TX 77807, USA.ORCID 0000-0002-0244-3556
Texas A&M Health Science Center · USTexas A&M University · USTufts University · US
Funding
CryoEM Data Collection Facility Consortium at NCMIU24GM116787 · NIGMS · STANFORD UNIVERSITY · PI BULLITT, ESTHER, CHIU, WAH · 2016 to 2020
$3.1M
Artificial Ecology Sink as prophylaxis against viral infectionDP2AI136600 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI CHEN, ZHILEI · 2017 to 2017
$2.2M
Immune-based therapy against STEC intoxication and HUSR01AI155457 · NIAID · TUFTS UNIVERSITY BOSTON · PI SHOEMAKER, CHARLES BIX, TZIPORI, SAUL R · 2021 to 2023
$1.4M
Internal Toxin Neutralizer for Treating STEC-infectionR21AI137803 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI CHEN, ZHILEI · 2019 to 2020
$432k
Broadly neutralizing non-antibody protein for treating clostridium difficile infectionR21AI126025 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI CHEN, ZHILEI · 2016 to 2017
$425k
Characterize essential regions in C. difficile toxin B for its neutralizationR21AI137696 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI ZHANG, JUNJIE · 2018 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Multi-Specific DARPin Potently Neutralizes Shiga Toxin 2 via Simultaneous Modulation of Both Toxin Subunits. · full record | OpenQuestion